Metabolon and MJFF Collaborate on Parkinson's Biomarker Discovery
Analysis based on 7 articles · First reported Mar 17, 2026 · Last updated Mar 18, 2026
This collaboration is expected to positively impact the biotechnology and pharmaceutical markets by accelerating biomarker discovery and therapeutic development for Parkinson's disease. It could lead to new diagnostic tools and treatments, benefiting companies involved in neurodegenerative research.
Metabolon, a leader in metabolomics solutions, announced a collaboration with The Michael J. Fox Foundation (MJFF) through the LRRK2 Investigative Therapeutics Exchange (LITE) program. This partnership aims to discover biomarkers and biological pathways associated with Parkinson's disease by leveraging Metabolon's Global Discovery Platform for comprehensive multiomics analyses across MJFF's Parkinson's Progression Markers Initiative (PPMI). The initiative seeks to improve early diagnosis and treatment of Parkinson's disease, which affects over 10 million people worldwide. The collaboration will integrate proteomic, lipidomic, and metabolomic data to identify patterns, including those reflecting LRRK2 activity, and support patient stratification and target engagement in future clinical studies. Ro Hastie, CEO of Metabolon, and Shalini Padmanabhan, Senior Vice President at MJFF, both highlighted the significance of this partnership in advancing Parkinson's research.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard